All News

Focusing therapeutic trials on 1 subtype of chronic obstructive pulmonary disease (COPD) can help lead to smaller, targeted studies, which in can help advance precision medicine, said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.